Principal Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.5M Buy
121,053
+628
+0.5% +$427K 0.04% 389
2026
Q1
$93M Buy
120,425
+800
+0.7% +$612K 0.05% 302
2025
Q4
$92.3M Buy
119,625
+1,142
+1% +$776K 0.05% 290
2025
Q3
$66.6M Sell
118,483
-4,766
-4% -$2.69M 0.03% 374
2025
Q2
$64.7M Sell
123,249
-6,376
-5% -$3.56M 0.03% 384
2025
Q1
$82.2M Sell
129,625
-865
-0.7% -$595K 0.05% 316
2024
Q4
$93M Sell
130,490
-42,602
-25% -$35.8M 0.05% 305
2024
Q3
$182M Buy
173,092
+2,828
+2% +$3.15M 0.1% 182
2024
Q2
$179M Buy
170,264
+1,852
+1% +$1.8M 0.11% 172
2024
Q1
$162M Buy
168,412
+37,685
+29% +$35.8M 0.1% 184
2023
Q4
$115M Sell
130,727
-628
-0.5% -$517K 0.07% 224
2023
Q3
$108M Sell
131,355
-1,672
-1% -$1.31M 0.08% 214
2023
Q2
$95.6M Sell
133,027
-3,241
-2% -$2.5M 0.07% 254
2023
Q1
$112M Buy
136,268
+1,614
+1% +$1.22M 0.08% 223
2022
Q4
$97.2M Sell
134,654
-9,777
-7% -$7.21M 0.07% 238
2022
Q3
$99.5M Buy
144,431
+14,963
+12% +$9.42M 0.08% 218
2022
Q2
$76.5M Buy
129,468
+3,323
+3% +$2.16M 0.06% 285
2022
Q1
$88.1M Buy
126,145
+264
+0.2% +$167K 0.06% 283
2021
Q4
$79.5M Sell
125,881
-2,415
-2% -$1.48M 0.05% 310
2021
Q3
$77.6M Buy
128,296
+2,682
+2% +$1.67M 0.05% 302
2021
Q2
$70.2M Sell
125,614
-6,296
-5% -$3.19M 0.05% 340
2021
Q1
$62.4M Sell
131,910
-9,970
-7% -$4.85M 0.04% 357
2020
Q4
$68.5M Sell
141,880
-6,275
-4% -$3.39M 0.05% 319
2020
Q3
$82.9M Sell
148,155
-3,617
-2% -$2.19M 0.07% 265
2020
Q2
$94.7M Buy
151,772
+34,093
+29% +$19.4M 0.08% 251
2020
Q1
$57.5M Buy
117,679
+6,645
+6% +$2.74M 0.06% 296
2019
Q4
$41.7M Sell
111,034
-3,453
-3% -$1.16M 0.03% 439
2019
Q3
$31.8M Buy
114,487
+1,639
+1% +$485K 0.03% 522
2019
Q2
$35.3M Sell
112,848
-2,952
-3% -$983K 0.03% 483
2019
Q1
$47.5M Buy
115,800
+712
+0.6% +$293K 0.04% 398
2018
Q4
$43M Sell
115,088
-1,543
-1% -$565K 0.05% 394
2018
Q3
$47.1M Buy
116,631
+2,315
+2% +$881K 0.04% 437
2018
Q2
$39.4M Buy
114,316
+442
+0.4% +$138K 0.04% 468
2018
Q1
$39.2M Sell
113,874
-295
-0.3% -$103K 0.04% 468
2017
Q4
$42.9M Buy
114,169
+2,087
+2% +$845K 0.04% 460
2017
Q3
$50.1M Sell
112,082
-3,119
-3% -$1.48M 0.05% 414
2017
Q2
$56.6M Buy
115,201
+2,646
+2% +$1.16M 0.06% 376
2017
Q1
$43.6M Buy
112,555
+2,263
+2% +$839K 0.05% 371
2016
Q4
$40.5M Sell
110,292
-404
-0.4% -$154K 0.05% 375
2016
Q3
$44.5M Sell
110,696
-1,275
-1% -$511K 0.06% 319
2016
Q2
$39.1M Buy
111,971
+2,350
+2% +$905K 0.05% 323
2016
Q1
$39.5M Buy
109,621
+3,038
+3% +$1.25M 0.06% 317
2015
Q4
$57.9M Buy
106,583
+2,198
+2% +$1.19M 0.09% 246
2015
Q3
$48.6M Buy
104,385
+3,236
+3% +$1.74M 0.08% 273
2015
Q2
$51.6M Buy
101,149
+4,346
+4% +$2.12M 0.08% 271
2015
Q1
$43.7M Buy
96,803
+2,007
+2% +$851K 0.07% 301
2014
Q4
$38.9M Buy
94,796
+2,855
+3% +$1.12M 0.06% 313
2014
Q3
$33.1M Sell
91,941
-6,359
-6% -$2.13M 0.06% 333
2014
Q2
$27.8M Sell
98,300
-965
-1% -$286K 0.05% 391
2014
Q1
$29.8M Buy
99,265
+2,189
+2% +$674K 0.05% 370
2013
Q4
$26.7M Buy
97,076
+758
+0.8% +$218K 0.05% 394
2013
Q3
$30.1M Buy
96,318
+2,806
+3% +$738K 0.06% 338
2013
Q2
$21M Buy
+93,512
New +$21.8M 0.05% 425

Other funds holding REGN

Principal Financial Group's REGN Position: Q2 2026 in Review

Principal Financial Group increased its Regeneron Pharmaceuticals (REGN) stake by 0.52% in Q2 2026, buying an estimated $427K and bringing the position to 121,053 shares worth $75.5M. The position accounts for 0.04% of the portfolio, ranked #389.

Principal Financial Group first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $182M in Q3 2024. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Principal Financial Group held 121,053 shares of Regeneron Pharmaceuticals worth $75.5M as of Q2 2026.
  • Principal Financial Group bought 628 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $427K.
  • Regeneron Pharmaceuticals made up 0.04% of Principal Financial Group's portfolio in Q2 2026, its #389 holding.
  • Principal Financial Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Principal Financial Group's Regeneron Pharmaceuticals position peaked at $182M in Q3 2024.
  • 1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.